Kymera Therapeutics Balance Sheet
NASDAQ: KYMRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kymera Therapeutics financial position
At the end of fiscal 2025, Kymera Therapeutics reported total assets of $1.74 billion, up 78.2% from a year earlier against total liabilities of $163.1 million. Shareholders' equity stood at $1.58 billion, or 90.6% of assets. The company held $357.0 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 10.47, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Kymera Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 357.01M | 120.26M | 109.97M | 68.39M | 47.98M | 31.00M | 76.02M |
| Short-Term Investments | 491.26M | 368.49M | 264.92M | 338.77M | 394.44M | 265.20M | 15.94M |
| Receivables | 0 | 0 | 15.00M | 0 | — | — | — |
| Total Current Assets | 871.21M | 510.27M | 405.32M | 419.42M | 451.27M | 302.34M | 92.84M |
| Property, Plant & Equipment | 43.17M | 50.46M | 48.13M | 13.33M | 11.88M | 10.84M | 3.79M |
| Long-Term Investments | 771.16M | 362.16M | 61.43M | 152.33M | 125.19M | 162.53M | — |
| Total Assets | 1.74B | 978.03M | 575.76M | 603.13M | 605.90M | 487.18M | 116.70M |
| Accounts Payable | 4.01M | 5.99M | 7.08M | 4.33M | 4.00M | 4.37M | 3.28M |
| Total Current Liabilities | 83.21M | 67.77M | 85.69M | 71.34M | 92.54M | 110.62M | 34.57M |
| Total Liabilities | 163.15M | 142.42M | 180.79M | 112.98M | 146.27M | 203.29M | 82.03M |
| Shareholders' Equity | 1.58B | 835.62M | 394.97M | 490.15M | 459.64M | 283.89M | -74.41M |
| Retained Earnings | -1.07B | -754.61M | -530.75M | -383.79M | -228.98M | -128.76M | -76.46M |
| Net Cash (Debt) | 848.28M | 488.74M | 374.88M | 407.17M | 442.42M | 296.20M | 91.96M |
| Shares Outstanding | 81.32M | 64.89M | 55.59M | 55.04M | 51.54M | 44.48M | 1.93M |
This table shows 7 annual periods of Kymera Therapeutics's balance sheet, from FY 2025 back to FY 2019, across 14 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow KYMR's reporting calendar. What is a balance sheet?